Siagoside

Drug Profile

Siagoside

Alternative Names: GM1; Sygen

Latest Information Update: 16 Jan 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fidia Farmaceutici
  • Class Gangliosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Spinal cord injuries; Stroke

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jan 2001 Data have been added to the Parkinson's Disease and Movement Disorders therapeutic trials and adverse events sections
  • 08 Jan 2001 Discontinued-Clinical for Parkinson's disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top